Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.
Hum Vaccin ImmunotherJul 2, 2026 (epub)
Xiaoqiang Liu, Yulin Jing, Xiuqing Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase III randomized controlled trial assessed the immunogenicity and safety of a porcine circovirus-free rotavirus vaccine (Rotarix PCV-free) compared to standard Rotarix in healthy Chinese infants aged 6-16 weeks. The study found that the seroconversion rate for Rotarix PCV-free was 84.9%, which met the non-inferiority criterion compared to 88.7% for Rotarix, with a difference of -3.73%.
Key findings
- Seroconversion rates were 84.9% for Rotarix PCV-free vs 88.7% for Rotarix, with a difference of -3.73%.
- The geometric mean concentration ratio for Rotarix PCV-free was 0.71, not meeting the non-inferiority threshold.
- The most common systemic adverse event was cough/runny nose, occurring in 30.6% of Rotarix PCV-free recipients.
- Serious adverse events were reported in 26.1% of Rotarix PCV-free and 25.2% of Rotarix recipients, none deemed vaccine-related.
Why it matters
Rotavirus vaccination is crucial for preventing severe diarrhea in young children. Understanding the immunogenicity and safety of new vaccine formulations helps inform vaccination strategies and public health policies.